Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Caristo Diagnostics
Deal Size : Undisclosed
Deal Type : Collaboration
Agepha Pharma and Caristo Diagnostics Team up to Fight Coronary Inflammation
Details : The collaboration will support clinical research involving the CaRi-Heart technology for coronary inflammation diagnostics and FDA-approved LODOCO (colchicine) tablets for therapeutic intervention.
Product Name : Lodoco
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Caristo Diagnostics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease
Details : LODOCO (colchicine, 0.5 mg tablet) through inhibition of beta-tubulin polymerization which is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization.
Product Name : Lodoco
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 20, 2023
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
